CHMA News and Press, Chiasma Inc. From 05/05/21

These Penny Stocks Continue to See Momentum as DogeCoin Smashes Records With penny stocks back in focus, investors are constantly looking for the best ones to watch. Now, as Cinco De Mayo is upon us, which penny stocks are showing heightened interest? For one, we are seeing a lot of...

Chiasma (CHMA) +39% on Q1 results.Athenex (ATNX) +31% on Kuur Therapeutics acquisition.Ault Global Holdings (DPW) +30% on preliminary Q1 results.iBio (IBIO) +26% after resolving Fraunhofer USA lawsuitBig 5 Sporting Goods Corporation (BGFV) +22% on Q1 results.DAVIDsTEA...

Chiasma (CHMA): Q1 GAAP EPS of -$0.49 misses by $0.18.Revenue of $1.86M beats by $0.1M.Cash, equivalents, and marketable securities of $115.0 million, as compared with $135.4 million as of December 31, 2020.Shares +44.01% PM.Press Release For further details see: Chiasma EPS misses by $...

Announced agreement to merge with Amryt Combination to create a global commercial stage rare and orphan disease leader with a diversified portfolio of therapies and a meaningful late-stage development pipeline Q1 2021 Net Product Revenues of $1.9M, a 100% increase over Q...

- Combined business will have three approved commercial products, lomitapide (Lojuxta®/Juxtapid®), metreleptin (Myalept®/ Myalepta®), octreotide (MYCAPSSA®) and a robust clinical pipeline - Lead pipeline product Oleogel-S10*(Filsuvez®) under regulat...

NEEDHAM, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, May 6, 2021 at 5:00 pm Eastern Time to discuss financial...

Chiasma (CHMA) announces long-term safety and efficacy data from the first 48 weeks of open-label extension ((OLE)) of Phase 3 CHIASMA OPTIMAL trial of Mycapssa (octreotide capsules) in in patients with acromegaly. Results show that the average insulin-like growth factor 1 (IGF-1) l...

Gainers: [[CHMA]] +13.7%. [[RAIL]] +8.3%. [[AMTX]] +7.7%. [[BBGI]] +6.6%. [[NEWT]] +4.9%.Losers: [[WVE]] -15.4%. [[RAVN]] -8.6%. [[DSP]] -7.9%. [[CLSD]] -7.7%. [[PYPL]] -5.7%. For further details see: CHMA, RAIL, WVE and RAVN among after-hours movers

--93% of all patients who enrolled as a responder to MYCAPSSA ® maintained their biochemical response at the end of the 48-week open-label extension (OLE) period-- --Safety profile during the OLE was generally consistent with the safety observed in the CHIASMA OPTIM...

Announcing new positive clinical data from its MPOWERED™ Phase 3 trial, Chiasma (CHMA) says MYCAPSSA has improved clinical symptoms and other patient-reported outcomes compared to long-acting injectable somatostatin receptor ligands (iSRLs) in patients with acromegaly.In the maint...